Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bertelsen

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Ugeskrift for Laeger|June 4, 1999
[Coordination of the treatment of cancer patients]K Bertelsen, H Rasmussen
Current Opinion in Oncology|September 1, 1993
Radiotherapy for gynecologic cancerK Bertelsen, A Jakobsen
Ugeskrift for Laeger|August 19, 1996
[Was chemotherapy beneficial for the patients with advanced ovarian cancer? A comparison of survival and resource use in two different time periods]K Bertelsen, A Kruhøffer
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 1994
Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusionK. Bertelsen, J.E. Andersen
Hospital & Community Psychiatry|August 1, 1973
Citizen participation in the development of acommunity mental health centerK Bertelsen, M R Harris
European Journal of Cancer & Clinical Oncology|July 1, 1987
Cyclic hormonal treatment in ovarian cancer. A phase-II trialA Jakobsen, K Bertelsen, A Sell
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 1, 1993
Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancerK. Bertelsen, B. Hølund, E. Andersen
Gynecologic Oncology|March 1, 1990
Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancerP Pfeiffer, O Bennedbaek, K Bertelsen
Gynecologic Oncology|January 1, 1995
A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapyP Sørensen, P Pfeiffer, K Bertelsen
European Journal of Immunology|April 1, 1988
An adjunct trait of HEL/I-Ab-specific T helper cell is sensitivity to antigen-specific immunosuppressionB A Araneo, T Dowell, K Bertelsen
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Ugeskrift for Laeger|June 4, 1999
[Coordination of the treatment of cancer patients]K Bertelsen, H Rasmussen
Current Opinion in Oncology|September 1, 1993
Radiotherapy for gynecologic cancerK Bertelsen, A Jakobsen
Ugeskrift for Laeger|August 19, 1996
[Was chemotherapy beneficial for the patients with advanced ovarian cancer? A comparison of survival and resource use in two different time periods]K Bertelsen, A Kruhøffer
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 1994
Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusionK. Bertelsen, J.E. Andersen
Hospital & Community Psychiatry|August 1, 1973
Citizen participation in the development of acommunity mental health centerK Bertelsen, M R Harris
European Journal of Cancer & Clinical Oncology|July 1, 1987
Cyclic hormonal treatment in ovarian cancer. A phase-II trialA Jakobsen, K Bertelsen, A Sell
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 1, 1993
Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancerK. Bertelsen, B. Hølund, E. Andersen
Gynecologic Oncology|March 1, 1990
Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancerP Pfeiffer, O Bennedbaek, K Bertelsen
Gynecologic Oncology|January 1, 1995
A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapyP Sørensen, P Pfeiffer, K Bertelsen
European Journal of Immunology|April 1, 1988
An adjunct trait of HEL/I-Ab-specific T helper cell is sensitivity to antigen-specific immunosuppressionB A Araneo, T Dowell, K Bertelsen
Pageof 8